Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - Aspen Pharma Pty Ltd, Cellabs Pty Ltd, ITL Healthcare Pty Ltd, Medical Concepts Australia Pty Ltd, Pathwest Laboratory Medicine WA, Sarstedt Australia Pty Ltd, The Australian Red Cross Blood Service, Rainbow and Nature Pty Ltd, Vital Diagnostics Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the manufacturing, distribution, and supply of therapeutic goods in Australia, thereby ensuring their quality, safety, and efficacy. This legislation addresses the gap in regulation of therapeutic goods, including medicines, medical devices, and blood products, by establishing a framework overseen by the Therapeutic Goods Administration (TGA). The objective of the Act is to protect public health by ensuring that only therapeutic goods that meet the necessary safety and quality standards are available in the market. The Parliament of Australia enacted this Act to formalise the regulation of therapeutic goods and provide the TGA with the authority to issue licences to manufacturers, monitor compliance, and take necessary actions such as revocation of licences when standards are not met.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration, applies to various entities including manufacturers, importers, and suppliers of therapeutic goods within Australia. This Act governs the regulation and control of therapeutic goods to ensure their safety, quality, and efficacy. The revocation of a manufacturer's licence, as indicated in this gazette, pertains to specific entities that have had their licences revoked at their request, which can include pharmaceutical companies, diagnostic service providers, and blood service divisions. The geographic reach of this Act is national, extending across all states and territories in Australia. While the Act applies broadly to the therapeutic goods industry, certain exclusions and exemptions may apply, often detailed in subordinate instruments that further elaborate on specific regulations, standards, or categories of goods. The revocation of licences, as described, is a direct application of the Act's provisions and demonstrates its enforcement mechanisms in maintaining compliance and quality within the therapeutic goods sector.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) allows the Secretary to revoke a licence to manufacture therapeutic goods, as specified under Section 41(1)(d). In this instance, the Secretary has revoked the licences of several companies, including Aspen Pharma Pty Ltd, Cellabs Pty Ltd, ITL Healthcare Pty Ltd, Medical Concepts Australia Pty Ltd, PathWest Laboratory Medicine WA, Sarstedt Australia Pty Ltd, The Australian Red Cross Blood Service, and Rainbow and Nature Pty Ltd, among others. This revocation was at the request of the manufacturers themselves. The obligations imposed by the Act on the entities involved include adhering to the manufacturing standards set out by the Therapeutic Goods Administration (TGA). These entities are required to ensure that any therapeutic goods they produce meet the quality, safety, and efficacy standards as prescribed by the TGA. Any breaches of these obligations could result in the revocation of their manufacturing licence. Failure to comply with the provisions of the Act can result in significant consequences. The Act stipulates various offences related to the manufacture of therapeutic goods, including the manufacture of goods without a valid licence, which can lead to criminal penalties. For instance, under Section 31 of the Act, a person who contravenes certain provisions can be subject to fines and imprisonment. The specific penalties depend on the nature and severity of the offence, but they can include substantial fines and imprisonment terms. Additionally, civil penalties may also apply, which could further include financial penalties and compensation orders.